Trofosfamide

Trofosfamide (INN) is a nitrogen mustard alkylating agent. It is sometimes abbreviated "TRO".[1] It has been used in trials to study its effects on ependymoma, medulloblastoma, sarcoma, soft tissue, supratentorial PNET, and recurrent brain tumors.[2]

Trofosfamide
Clinical data
Trade namesIxoten
AHFS/Drugs.comInternational Drug Names
Routes of
administration
By mouth (film-coated tablets)
ATC code
Legal status
Legal status
  • DE: § 48 AMG/§ 1 MPAV (Prescription only)
Identifiers
IUPAC name
  • N,N,3-tris(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amide 2-oxide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard100.040.686
Chemical and physical data
FormulaC9H18Cl3N2O2P
Molar mass323.58 g·mol−1
3D model (JSmol)
SMILES
  • C1CN(P(=O)(OC1)N(CCCl)CCCl)CCCl
InChI
  • InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2 N
  • Key:UMKFEPPTGMDVMI-UHFFFAOYSA-N N
 NY (what is this?)  (verify)

References

  1. Jahnke K, Thiel E, Bechrakis NE, et al. (December 2008). "Ifosfamide or trofosfamide in patients with intraocular lymphoma". J. Neurooncol. 93 (2): 213–7. doi:10.1007/s11060-008-9761-8. PMID 19099202. S2CID 33892177.
  2. "Trofosfamide". www.drugbank.ca. Retrieved 2019-12-19.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.